Francesca Gilli

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.

Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.

Interferon-beta responders and non-responders. A biological approach.

Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica.

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients.

Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.

Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis.

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.

Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.

Chemokine biomarkers in central nervous system tissue and cerebrospinal fluid in the Theiler's virus model mirror those in multiple sclerosis.

The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

The effect of B-cell depletion in the Theiler's model of multiple sclerosis.

High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.

Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.

Clinical utility of a molecular signature in inflammatory demyelinating disease.

Differential neuro-immune patterns in two clinically relevant murine models of multiple sclerosis.

Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.